For how we live.
In DeLLphi-305, 563 patients whose small-cell lung cancer was stable after chemoimmunotherapy were randomised. Median survival was 21.1 months with tarlatamab plus durvalumab versus 12.7 with durvalumab alone.
In a phase 3 trial, tambotatug pelitecan extended median survival to 13.3 months versus 9.4 on standard chemotherapy — but the trial was open-label and run entirely in China.
The European Medicines Agency's March meeting produced five positive opinions, three of them for orphan-designated cancer and rare-disease treatments already available in some other markets.